Viridian Therapeutics is a technology company.
Viridian Therapeutics has raised $89.0M across 6 funding rounds.
Viridian Therapeutics has raised $89.0M in total across 6 funding rounds.
I need to clarify an important point: Viridian Therapeutics is not a technology company—it is a biopharmaceutical company focused on developing medicines for autoimmune and rare diseases.
Based on the search results provided, here's what we know about Viridian:
Viridian Therapeutics is a biopharmaceutical company leveraging antibody discovery and engineering expertise to develop optimized treatments for rare autoimmune conditions[1][2]. The company was founded with a mission to significantly improve treatment options for autoimmune and rare diseases, with a particular focus on thyroid eye disease (TED)[1]. Viridian aims to provide patients with therapies that are safe, effective, and easy to use, enabling them to live full, healthy lives[1].
The search results provided contain limited details about Viridian's founding history, specific product pipeline, financial performance, or market position. To provide a comprehensive analysis matching your requested framework (origin story, role in broader landscape, and future outlook), additional sources would be needed covering the company's founding timeline, key leadership backgrounds, clinical trial data, and competitive positioning within the biopharmaceutical sector.
If you're researching Viridian as a potential investment or partnership opportunity, I'd recommend seeking more detailed information about their clinical pipeline, regulatory status, and market opportunity in rare autoimmune diseases.
Viridian Therapeutics has raised $89.0M in total across 6 funding rounds.
Viridian Therapeutics's investors include Atlas Venture, MPM Capital, Broadview Ventures.
Viridian Therapeutics has raised $89.0M across 6 funding rounds. Most recently, it raised $41.0M Series C in November 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2015 | $41.0M Series C | Atlas Venture, MPM Capital | |
| Feb 1, 2015 | $9.0M Series B | Atlas Venture, Broadview Ventures, MPM Capital | |
| Jun 1, 2014 | $7.0M Series B | Atlas Venture, Broadview Ventures, MPM Capital | |
| Apr 1, 2012 | $20.0M Series B | Atlas Venture, Broadview Ventures, MPM Capital | |
| Jun 1, 2009 | $4.0M Series A | Atlas Venture, MPM Capital | |
| May 1, 2008 | $8.0M Series A | Atlas Venture, MPM Capital |